Dual Inhibition of CDK4/6 and CDK7 Suppresses Triple‐Negative Breast Cancer Progression via Epigenetic Modulation of SREBP1‐Regulated Cholesterol Metabolism by Yilan Yang, Jiatao Liao, Zhe Pan, Jin Meng, Li Zhang, Wei Shi, Xiaofang Wang, Xiaomeng Zhang, Zhirui Zhou, Jurui Luo, Xingxing Chen, Zhaozhi Yang, Xin Mei, Jinli Ma, Zhen Zhang, Yi‐Zhou Jiang, Zhi‐Min Shao, Fei Xavier Chen, Xiaoli Yu, Xiaomao Guo

Subjects: Get full text

Identification of new inhibitors of the kinase acti­vity of CDK2 and CDK9 by molecular modeling and high-efficiency screening by G.V. Andrianov, I.G. Serebriiskii

Subjects: Get full text

Validation of a hypomorphic variant in CDK13 as the cause of CHDFIDD with autosomal recessive inheritance through determination of an episignature by Jan Fischer, Mariëlle Alders, Marcel M. A. M. Mannens, David Genevieve, Karl Hackmann, Evelin Schröck, Bekim Sadikovic, Joseph Porrmann

Subjects: “…CDK13…”
Get full text

Suppression of microtubule acetylation mediates the anti-leukemic effect of CDK9 inhibition by Xi Xie, Baoyuan Zhang, Donghe Li, Jiaming Gao, Jiaoyang Li, Chenxuan Liu, Yuqing Dan, Pengfei Xu, Lei Yan, Xu Huang, Rui Zhang, Yunying Yao, Wei Huang, Jiawei Nie, Xinru Wang, Bo Jiao, Ruibao Ren, Ping Liu

Subjects: “…CDK9…”
Get full text

Computational design of CDK1 inhibitors with enhanced target affinity and drug-likeness using deep-learning framework by Zuokun Lu, Jiayuan Han, Yibo Ji, Bingrui Li, Aili Zhang

Subjects: Get full text

اصطناع بعض مشتقات الإيزاتين ودراسة فعاليتها المضادة للسرطان حاسوبياً بوصفها مثبطات محتملة لإنزيم CDK2... by حياة الروبة, فاروق قنديل, فرانسوا قرة بت

Subjects: Get full text

Low-Grade Uterine Adenosarcoma with Overexpression of MDM2 and CDK4 by Immunohistochemistry: A Case Report and Literature Review by Yumiko Miyazaki, Aina Yamaguchi, Hitomi Nanbu, Akiko Shinagawa, Mana Fukushima, Makoto Orisaka, Yoshio Yoshida

Subjects: Get full text

HNRNPD regulates the biogenesis of circRNAs and the ratio of mRNAs to circRNAs for a set of genes by Shuhui Chang, Yucong Wang, Xiaolin Wang, Hanyuan Liu, Tao Zhang, Yangge Zheng, Xueren Wang, Ge Shan, Liang Chen

Subjects: Get full text

The Role Of Time Delays, Slow Processes And Chaos In Modulating The Cell-Cycle Clock by E.V. Presnov, Z. Agur

Subjects: Get full text

Discovery of novel and potent CDK8 inhibitors for the treatment of acute myeloid leukaemia by Zhuoying Chen, Quan Wang, Yao Yao Yan, Dalong Jin, Yumeng Wang, Xing Xing Zhang, Xin Hua Liu

Subjects: “…CDK8 inhibitor…”
Get full text

Manipulating mitochondrial reactive oxygen species alters survival in unexpected ways in a Drosophila Cdk5 model of neurodegeneration by Andrew P. K. Wodrich, Brent T. Harris, Edward Giniger

Subjects: “…cdk5…”
Get full text

Targeting the cyclin-dependent kinase family in anticancer drug discovery: From computational to experimental studies by Priyanka Solanki, Shubhangi Sarwadia, Mohd Athar, Prakash C. Jha, Anu Manhas

Subjects: “…CDK enzymes…”
Get full text

CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells by Graziana Digiacomo, Claudia Fumarola, Silvia La Monica, Mara Bonelli, Andrea Cavazzoni, Maricla Galetti, Rita Terenziani, Kamal Eltayeb, Francesco Volta, Silvia Zoppi, Patrizia Bertolini, Gabriele Missale, Gabriele Missale, Roberta Alfieri, Pier Giorgio Petronini

Subjects: Get full text

Impacts of genomic alterations on the efficacy of HER2-targeted antibody–drug conjugates in patients with metastatic breast cancer by Riqing Huang, Anqi Hu, Qixiang Rong, Ditian Shu, Meiting Chen, Wei Yang, Yue Zhang, Qiufan Zheng, Xin An, Cong Xue, Haifeng Li, Yanxia Shi

Subjects: Get full text

Integrating traditional biomarkers and emerging predictors to assess neoadjuvant chemotherapy efficacy in breast cancer: a multifactorial analysis of Ki-67, CDK4, EGFR, TILs and ct... by Tianzhao Du, Ye Yuan, Shulan Sun, Zhichao Gao, Xiaoshuai Li

Subjects: Get full text

The efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in the adjuvant treatment of patients with high-risk invasive HR+/HER2-e... by Merve Keskinkilic, Mehmet Emin Arayici, Yasemin Basbinar, Hulya Ellidokuz, Tugba Yavuzsen, Ilhan Oztop

Subjects: Get full text

Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study by Seda Kahraman, Mutlu Hizal, Burcin Cakan Demirel, Deniz Can Guven, Ozge Gumusay, Basak Oyan Uluc, Ertugrul Bayram, Burcu Gulbagci, Alper Yasar, Sena Ece Davarci, Eda Eylemer Mocan, Omer Acar, Deniz Isik, Esra Aydin, Yusuf Karakas, Melike Ozcelik, Murat Keser, Sadi Kerem Okutur, Onder Eren, Serkan Menekse, Dincer Aydin, Funda Yilmaz, Ozlem Dogan, Gulhan Ozkanli, Hakan Yucel, Veli Sunar, Musa Baris Aykan, Ozlem Ozdemir, Berna Bozkurt Duman, Merve Keskinkilic, Teoman Sakalar, Ali Inal, Muge Karaoglanoglu, Asude Aksoy, Muhammed Muhiddin Er, Nazim Serdar Turhal, Nurhan Onal Kalkan, Mehmet Ali Nahit Sendur

Subjects: “…CDK 4/6 inhibitors…”
Get full text

CDK5在吗啡依赖诱导神经细丝蛋白过度磷酸化中的作用

Subjects: Get full text

Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells by Graziana Digiacomo, Claudia Fumarola, Silvia La Monica, Mara Bonelli, Andrea Cavazzoni, Maricla Galetti, Rita Terenziani, Kamal Eltayeb, Francesco Volta, Silvia Zoppi, Patrizia Bertolini, Gabriele Missale, Gabriele Missale, Roberta Alfieri, Pier Giorgio Petronini

Subjects: Get full text

Discovery of novel CDK2 inhibitors for cancer treatment: integrating ligand-based pharmacophore modelling, molecular docking, DFT, ADMET, and molecular dynamics simulation studies by Bharath Kumar Chagaleti, Venkatesan Saravanan, M. K. Kathiravan

Subjects: Get full text